892121-52-7

Upstream product

• 722-92-9 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 994-30-9 triethylsilyl chloride 

Downstream Products

• 913619-35-9 phenyl-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenylamino]-acetic acid methyl ester 
• 872690-45-4 N-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-acetamide 
• 913619-61-1 3-[4-(2-{[2-chloro-4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-ethyl-amino}-2-phenyl-ethoxy)-phenyl]-propionic acid methyl ester 
• 913619-60-0 [4-(2-{[2-chloro-4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-ethyl-amino}-2-phenyl-ethoxy)-phenyl]-acetic acid methyl ester 
• 913619-49-5 2-{[2-chloro-4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-ethyl-amino}-2-phenyl-ethanol 
• 913619-59-7 4-(2-{[2-chloro-4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-ethyl-amino}-2-phenyl-ethoxy)-benzoic acid methyl ester 
• 913619-65-5 2-{ethyl-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-N,N-dimethyl-2-phenyl-acetamide 
• 872690-59-0 2-{ethyl-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-2-phenyl-ethanol 
• 913619-66-6 (R)-2-{Ethyl-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-2-phenyl-ethanol 
• 913619-67-7 (S)-2-{Ethyl-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-2-phenyl-ethanol 
• 872690-60-3 2-{ethyl-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-1-phenyl-ethanol 

Relevant academic research and scientific papers

Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRα and β

A series of branched and unbranched anilinohexafluoroisopropanols related to the known sulfonamide T0901317 were prepared and evaluated as activators/modulators of both LXRα and LXRβ. A structure-activity relationship was established and compounds with high potency on both the receptors were identified. Many compounds showed a tendency toward selectivity for LXRβ versus LXRα. Several analogues were evaluated for effects on plasma lipoprotein levels in mice. A few of these significantly raised HDL-cholesterol levels in plasma but showed markedly different effects on liver triglyceride content, suggesting that this series may yield candidates with improved efficacy/safety profiles compared to existing molecules.

Novel hexafluoroisopropanol substituted cyclohexane derivatives

The invention is concerned with novel hexafluoroisopropanol substituted cyclohexane derivatives of formula (I) wherein R1 to R4, X, m and n are as defined in the description and in the claims, as well as physiologically acceptable sa